Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Top
  • View PDF
  • Download citation information
  • Send a comment
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal
  • Top
  • Abstract
  • Version history
Article has an altmetric score of 9

See more details

Referenced in 11 patents
80 readers on Mendeley
  • Article usage
  • Citations to this article (250)

Advertisement

Research Article Free access | 10.1172/JCI114984

Lack of HLA class I antigen expression by cultured melanoma cells FO-1 due to a defect in B2m gene expression.

C M D'Urso, Z G Wang, Y Cao, R Tatake, R A Zeff, and S Ferrone

Department of Microbiology and Immunology, New York Medical College, Valhalla 10595.

Find articles by D'Urso, C. in: JCI | PubMed | Google Scholar

Department of Microbiology and Immunology, New York Medical College, Valhalla 10595.

Find articles by Wang, Z. in: JCI | PubMed | Google Scholar

Department of Microbiology and Immunology, New York Medical College, Valhalla 10595.

Find articles by Cao, Y. in: JCI | PubMed | Google Scholar

Department of Microbiology and Immunology, New York Medical College, Valhalla 10595.

Find articles by Tatake, R. in: JCI | PubMed | Google Scholar

Department of Microbiology and Immunology, New York Medical College, Valhalla 10595.

Find articles by Zeff, R. in: JCI | PubMed | Google Scholar

Department of Microbiology and Immunology, New York Medical College, Valhalla 10595.

Find articles by Ferrone, S. in: JCI | PubMed | Google Scholar

Published January 1, 1991 - More info

Published in Volume 87, Issue 1 on January 1, 1991
J Clin Invest. 1991;87(1):284–292. https://doi.org/10.1172/JCI114984.
© 1991 The American Society for Clinical Investigation
Published January 1, 1991 - Version history
View PDF
Abstract

The melanoma cell line FO-1 does not express HLA class I antigens and does not acquire them on the cell surface after incubation with IFN-gamma. Immunochemical studies showed that FO-1 cells synthesize HLA class I heavy chain, but do not synthesize beta 2-microglobulin (beta 2-mu). The latter abnormality is associated with lack of beta 2-mu mRNA which remains undetectable in FO-1 cells incubated with IFN-gamma. The defect was identified as a genetic lesion in the B2m gene, since DNA hybridization analysis detected a deletion of the first exon of the 5'-flanking region, and of a segment of the first intron of the B2m gene. HLA class I antigen expression was reconstituted on melanoma cells FO-1 after transfection with the wild-type mouse B2m gene, thereby confirming the abnormality of the endogenous B2m gene. The defect identified in FO-1 cells is distinct from that underlying the lack of HLA class I antigen expression by lymphoblastoid cells Daudi, but is remarkably similar to that causing lack of H-2 class I antigen expression by mouse lymphoblastoid cells R1 (TL-). These results suggest that genetic recombination in the 5' region of the B2m gene is a recurrent mechanism in B2m gene defects. In addition to contributing to our understanding of molecular abnormalities in HLA class I antigen expression by melanoma cells, FO-1 cells represent a useful model for analyzing the role of HLA class I antigens in the biology of melanoma cells and in their interaction with cells of the immune system.

Images.

Browse pages

Click on an image below to see the page. View PDF of the complete article

icon of scanned page 284
page 284
icon of scanned page 285
page 285
icon of scanned page 286
page 286
icon of scanned page 287
page 287
icon of scanned page 288
page 288
icon of scanned page 289
page 289
icon of scanned page 290
page 290
icon of scanned page 291
page 291
icon of scanned page 292
page 292
Version history
  • Version 1 (January 1, 1991): No description

Article tools

  • View PDF
  • Download citation information
  • Send a comment
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal

Metrics

Article has an altmetric score of 9
  • Article usage
  • Citations to this article (250)

Go to

  • Top
  • Abstract
  • Version history
Advertisement
Advertisement

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts

Referenced in 11 patents
80 readers on Mendeley
See more details